ReviewMedComm2026
Ischemic Stroke and Traumatic Brain Injury: Epidemiology, Molecular Pathways, and Emerging Therapies.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke and traumatic brain injury are two leading causes of death and long-term disability worldwide. Despite their different primary insults, both conditions trigger a complex cascade of secondary brain injury that largely determines neurological outcome. This review systematically compares the epidemiology, shared molecular pathways, and emerging therapeutic strategies for secondary brain injury after ischemic stroke and traumatic brain injury. We focus on three interconnected pathological cascades spanning blood-brain barrier disruption, neuroinflammation, and neuronal death driven by excitotoxicity, oxidative stress, and multiple forms of programmed cell death. For each pathway, we highlight convergent and divergent mechanisms between the two disorders. We then summarize emerging preclinical interventions ranging from small molecule inhibitors and repurposed drugs to nanomedicine, extracellular vesicles, and neuromodulation techniques. In parallel, we review recent and ongoing clinical trials targeting these pathways, emphasizing mechanism-based strategies. Finally, we discuss current challenges and offer future perspectives on biomarker-driven patient stratification, innovative drug delivery systems bypassing the blood-brain barrier, and multitarget combination regimens. By providing a unified framework that compares ischemic stroke and traumatic brain injury side by side, this review aims to guide the development of more effective, personalized treatments for secondary brain injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.